IPSEN (OTCMKTS:IPSEY) Short Interest Update

IPSEN (OTCMKTS:IPSEY) was the target of a large decline in short interest in September. As of September 15th, there was short interest totaling 41 shares, a decline of 96.6% from the August 31st total of 1,214 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 2,201 shares, the days-to-cover ratio is presently 0.0 days.

IPSEN Stock Up 0.0%

IPSEY traded up $0.01 on Friday, hitting $41.98. The company had a trading volume of 1,642 shares, compared to its average volume of 618. The company’s fifty day moving average price is $46.11 and its 200 day moving average price is $46.56. IPSEN has a 1-year low of $32.02 and a 1-year high of $51.10.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on IPSEY shares. Zacks Research upgraded IPSEN to a “hold” rating in a report on Friday, May 29th. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Jefferies Financial Group lowered shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Finally, Barclays upgraded shares of IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, IPSEN has a consensus rating of “Hold”.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.